The effect of plasma on degradation of human growth hormonereleasing hormone (GRH) was examined in vitro and in vivo using high performance liquid chromatography (HPLC), radioimmunoassay (RIA), and bioassay. When GRH(1-44)-NH2 was incubated with human plasma, the t1/2 of total GRH immunoreactivity was 63 min (RIA). However, HPLC revealed a more rapid disappearance (t1/2, 17 min) of GRH(144)-NH2 that was associated with the appearance of a less hydrophobic but relatively stable peptide that was fully immunoreactive. Sequence analysis indicated its structure to be GRH(344)-NH2. Identity was also confirmed by co-elution of purified and synthetic peptides on HPLC. Biologic activity of GRH(344)-NH2 was <10-3 that of GRH(144)-NH2. After intravenous injection of GRH(1-44)-NH2 in normal subjects, a plasma immunoreactive peak with HPLC retention comparable to GRH(344)-NH2 was detected within 1 min and the tl/2 of GRH(144)-NH2 (HPLC) was 6.8 min. The results provide evidence for GRH inactivation by a plasma dipeptidylaminopeptidase that could limit its effect on the pituitary.
Introduction
Growth hormone (GH)l-releasing hormone (GRH) was first identified and sequenced in tumors from which it was ectopically secreted (1) (2) (3) . Two forms ofGRH, GRH( 1-40)-OH and GRH(l-44)-NH2, that have been identified from both tumors and hypothalamus, are identical in structure (4) , exhibit indistinguishable biologic activity, and are derived from a single precursor (5) .
We have previously described a sensitive and specific radioimmunoassay (RIA) for human GRH(1-40)-OH that was utilized for the determination of metabolic clearance and plasma disappearance rates (6) . The kinetics ofdisappearance ofGRH( 1-40)-OH after a single intravenous injection, as measured by RIA, was best explained by a two-pool model with an equilibration 1. Abbreviations used in this paper: ACN, acetonitrile; CRF, corticotropinreleasing factor; DAP, dipeptidylaminopeptidase; GH, growth hormone; GRH, growth hormone-relvasing hormone; HPLC, high performance liquid chromatography; TFA, trifluoroacetic acid; UV, ultraviolet. t1/2 of 8 min and an elimination t/2 of 52 min that was independent of dose within the 1-10 sg/kg range. Validation of our measurements in this initial study was based on coelution on gel filtration ofplasma immunoreactivity and synthetic GRH( 1-40)-OH. The elimination half-time was similar to that observed after discontinuation of a constant infusion of GRH(1-40)-OH and was comparable to results subsequently reported by others (7) . The disappearance rate was also similar to that reported for ovine corticotropin-releasing factor (CRF) (8) , another releasing hormone of similar size, but was considerably longer than that of other hypothalamic hormones (9-1 1) and of ACTH (12), a pituitary hormone of comparable size.
With the subsequent report that human CRF exhibited much more rapid clearance than that of ovine CRF from plasma (13), we considered the possibility that our initial results and those of others could be explained by metabolic conversion of GRH within the plasma compartment to another immunQreactive compound(s) with a metabolic clearance rate slower than that of GRH. The present studies were therefore designed to more critically define the molecular form(s) of GRH in plasma after its injection and to search for differences in the clearance ofsuch forms from plasma, if present.
Methods

Clinical studies
Subjects studied. Experiments were performed in eight healthy adult male subjects whose ages ranged from 22 to 29 yr and who gave informed written consent. Studies were conducted in the General Clinical Research Center of the University of Cincinnati Hospital, Cincinnati, OH. All subjects had fasted for the preceding 8 h. An indwelling butterfly needle was placed in a vein in each forearm and kept patent with heparinized saline for injection and blood sampling. 
Amino acid analysis and sequencing
The isolated metabolite was subjected to structure analysis. Amino acid analysis was performed on an instrument employing postcolumn reaction with fluorescamine (15) . Microsequence analysis was carried out on a sequencer (model 470A; Applied Biosystems, Inc., Foster City, CA) (16) . PTH-amino acids at each cycle were identified by HPLC (17) .
Synthesis ofpeptides
GRH(1-44)-NH2 and related peptides were synthesized by the Merrifield solid-phase procedure using sequential additions ofthe t-butyloxycarbonyl (Boc)-protected amino acids to the H-Leu-benzhydrylamine resin (18, 19) . After cleavage from the resin with anhydrous liquid hydrogen fluoride, the crude peptide was purified by preparative HPLC with system C. The peptides were shown to be homogeneous by analytical HPLC with system D. After hydrolysis in 6 N HCl containing 1% thioglycolic acid, the peptides gave the expected amino acid composition.
RIA for GRH
Plasma extracts and HPLC fractions were assayed for GRH immunoreactivity by a double-antibody RIA, as previously described (6, 14) . The 50% effective dose for the GRH(1-40)-OH standard was 14 fmol/tube with intra-and interassay coefficients of variation of 8.9% and 12.0%, respectively, for these experiments. GRH( 1-44)-NH2 exhibits 60% crossreactivity with parallel displacement to the GRH(1-40)-OH reference standard in this assay system.
Bioassay for GRH
Monolayer cultures of dispersed pituitary cells from adult male SpragueDawley rats (Harlan Sprague-Dawley, Inc., Indianapolis, IN) were prepared as previously described (14, 20) . After a 72-h culture period, the cells were exposed during a 4-h incubation to synthetic GRH(1-44)-NH2
and/or synthetic GRH(3-44)-NH2 (lot # 1 166-287; Hoffmann-La Roche, Inc.), or to partially purified GRH(3-44)-NH2 from in vitro plasma incubations. Rat GH secreted into the medium was measured by a specific RIA (21) and the results expressed in terms of an NIADDK rat GH RP-1 reference standard. The intraassay coefficient of variation for the rat GH assay was 3.1%.
Data analyses
Plasma disappearance curves of human GRH were determined by biexponential analysis using the SAAM 27 curve fitting computer program (6) , as adapted to a DEC (Digital Equipment Corp., Maynard, MA) VAX computer (CONSAM). Results are expressed as mean±SEM and the significance of differences between group means were determined by the I test. The relative potency of the metabolite in the in vitro bioassay was determined by covariance analysis.
Results
Incubation ofGRH(1-44)-NH2 with human plasma in vitro
The incubation of 100 ,ug GRH( 1-44)-NH2 with human plasma in vitro initially revealed a disappearance t1/2 of 63 min based on RIA oftotal GRH immunoreactivity remaining in the plasma extract (data not shown). However, after HPLC separation of the extracts using system A, a much more rapid disappearance of true GRH(l-44)-NH2 was observed, as seen in Fig Concomitant with the disappearance of GRH(1-44)-NH2 from incubated plasma in vitro was the appearance of a less hydrophobic, immunoreactive metabolite which coeluted with an endogenous plasma protein at -18 min (Fig. 1) . The concentration of this peptide, quantitated by RIA or by integration of the area under the curve after subtracting the area of the endogenous plasma protein, is also shown in Fig. 2 . The quantity of this metabolite exceeded that of human GRH(1-44)-NH2 by -25 min and remained relatively constant during the remainder of the incubation period.
Identification and characterization ofthe GRH metabolite
Amino acid and sequence analysis. The major immunoreactive metabolite peak from the 30-and 60-min incubations was pooled and separated from the coeluting contaminant present in plasma by use of another HPLC system (system B). The amino acid composition of this material revealed the loss of one tyrosine and one alanine residue from the expected composition of GRH(1-44)-NH2. These residues represent positions 1 and 2, respectively, ofthe native peptide. Sequence analysis ofthe metabolite revealed the NH2-terminal residue to be aspartate, which is normally present in position 3 (Fig. 3) .
Chromatography. Additional evidence of the identity of the metabolite as GRH(3-44)-NH2 was provided by co-chromatography of the purified metabolite and synthetic GRH(3-44)-NH2 line is the additional absorbance contributed by GRH. The absorbance patterns at 5 through 120 min are shown in the other panels. The GRH metabolite peak that eluted at 18 min and increased with time through 30 min coeluted with an endogenous plasma peak, evident at 0 min in interrupted lines, using chromatographic system A.
using system C. The elution pattern of 1. HLTyr-Aa. 
Incubation ofGRH(3-44)-NH2 and GRH(1-40)-OH
with human plasma in vitro When synthetic GRH(3-44)-NH2 was incubated with human plasma under the identical conditions as described for GRH(1-44)NH2, a decrease in the GRH(3-44)NH2 UV absorption peak on HPLC occurred with time, though at a considerably slower rate than observed with GRH(l-44)-NH2 (Fig. 6) 
Plasma disappearance rates ofGRH immunoreactivity and GRH(J-44)-NH2
A comparison of the plasma disappearance curves of GRH(l-44)-NH2 and of total immunoreactive GRH after intravenous kg. Blood samples were centrifuged and plasma extracted immediately after withdrawal. The conditions of chromatography were as in system A except that another Vydac column was used. Shown are the results injection ofGRH( -44)-NH2 is shown in Fig. 8 . The true GRH(l-44)-NH2 concentration was determined by integration of the GRH(l-44)-NH2 peak (as determined by RIA) on the HPLC analysis of plasma from each subject at each time point. The distribution (t112 a) and elimination (t1/2 Al) phase half-times for total GRH immunoreactivity were 2.7±0.6 and 16.0±1.2 min, and for GRH(l-44)-NH2 were 1.0±0.2 and 6.8±1.2 min. (P < 0.05 and P < 0.001), respectively. Shown for comparison in the interrupted line is the disappearance curve for the combined series of injections of GRH(1-40)-OH, as previously reported (6).
Discussion
The results of the present studies clearly indicate that exposure of GRH(l-44)-NH2 to plasma results in rapid degradation to a peptide that is modified at the NH2 terminus and exhibits considerable differences in biologic and pharmacokinetic properties. These studies were prompted by the apparent inconsistency of our previous metabolic clearance results with the findings reported for other hypothalamic hormones. Although we raised the possibility ofin vivo GRH metabolism during our continuous infusion studies (6), the constant infusion of fresh GRH(1-40)- of a single subject. Similar results were observed in five other subjects. In most subjects, no detectable immunoreactive peak at the elution position of GRH(1-44)NH2 was seen beyond 15 min. The earlier eluting peak of immunoreactivity coincided with that of synthetic GRH(3-44)-NH2.
OH into plasma, together with the limited resolving capability ofgel filtration chromatography, resulted in our inability to distinguish between the native hormone and the metabolite degraded at the NH2 terminus. The improved resolution ofHPLC clearly indicated, however, that GRH was being rapidly metabolized both in vivo and in vitro.
We initially performed in vitro studies because the concentrations of GRH that could be used were readily detectable by UV absorption, thereby precluding the need for either radioiodinated hormone, which might exhibit different degradation characteristics, as has been shown for insulin (22) , or reliance on RIA for quantification, since immunoreactivity ofthe possible metabolites could vary considerably. The results demonstrated that the disappearance of GRH(l-44)-NH2 in vitro was considerably more rapid than that ofeither GRH( 1-40)-OH (6) or total GRH(1-44)-NH2 immunoreactivity in vivo. Based on the structure of GRH, we initially suspected that the cleavage would occur at positions 1 1-12 or 20-21, the sites of dibasic residues susceptible to the action of trypsin-like enzymes. The retention of full immunoreactivity by the metabolite (on the basis of UV absorption) suggested that there was relatively limited size change in the number of residues and, therefore, that the site of degradation was near the NH2 terminus, since the antibody rec- ognition sites were on the COOH-terminal portion of the molecule (14) .
Amino acid composition and sequence analysis of the metabolite revealed that, indeed, the molecule was reduced in size by removal of only two residues at the amino terminus. Sequencing was repeated on several different purified preparations and gave identical results. Confirmation of the sequence was demonstrated by coelution of synthetic and enzymatically converted GRH(3-44)-NH2 on HPLC and by indistinguishable bioactivity and immunoreactivity.
The bioactivity of GRH(3-44)-NH2 in a cultured pituitary cell system was reduced by a factor of >5,000, as would have been expected on the basis of previous studies that demonstrated the critical importance of the NH2 terminal region of the molecule (23) (24) (25) The present results, at first inspection, appear inconsistent with the characterization of endogenous GRH in normal subjects (29) and in patients with GRH-secreting tumors (14, 26) were associated with a secondary increase in plasma GH levels at 2-3 h. This was attributed to the persistence of a maximally stimulating concentration of GRH in circulation for the entire time period. This conclusion is no longer tenable, given the rapid half-time of GRH. Although a parallel in vivo study of GRH(1-40)-OH has not been performed, extrapolation of the in vitro data results in an estimated elimination tl/2 of 10 min. Thus, alternative explanations, relating to changes in the intracellular response to GRH or to changes in somatostatin secretion, appear more plausible. Other published data relating to plasma GRH levels after injection of exogenous GRH (32) (33) (34) are also likely to be incorrect, since the contribution of GRH metabolites to total measured GRH immunoreactivity is unknown. Finally, our results should be helpful in designing modifications of the GRH sequence that are resistant to enzymatic degradation in order to develop superactive analogs. Since enhanced growth in human GH deficiency can be achieved in some patients with continuous as well as intermittent GRH administration (35) , the availability of more potent analogs will be of considerable clinical importance.
